OncoMatch/Clinical Trials/NCT03579836
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Is NCT03579836 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including BEY1107 and Gemcitabine for locally advanced or metastatic pancreatic cancer.
Treatment: BEY1107 · Gemcitabine — This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: any therapy for locally advanced and/or metastatic pancreatic cancer
A patient who has treatment history with locally advanced and/or metastatic pancreatic cancer
Lab requirements
Blood counts
Adequate Bone marrow function at screening
Kidney function
Adequate Renal function at screening
Liver function
Adequate Liver function at screening
Adequate Bone marrow, Renal and Liver function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03579836 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages